My HappyStock
Log in to track your learning progress.
Korean Companies
Find my preferred stocks →Compare companies across six criteria and explore businesses that fit your priorities.
Alteogen Inc. (196170)
Average score 7.6 B
Preference —
Alteogen Inc. (corporate logo/trademark); image hosted by SemoLogo/Vibers
Six company scores
ALT-B4 licensing and royalties drive rapid growth
High margins from technology licensing income
Large liquid assets and minimal borrowings
Patented platform and major pharma partnerships
SC drug conversions and new deals offer upside
Rich earnings multiple and lumpy licensing revenues
Editorial scores are for education, not audited financial metrics or investment advice.
Revenue by business
- ALT-B4 licensing 82.8%
Upfront fees, milestones and SC platform licensing
- ALT-L9 biosimilar 8.2%
Eylea biosimilar licensing and commercialization fees
- Other licensing services 2.3%
Other technology fees and partner royalties
- Merchandise sales 6.4%
Medicines resold by the subsidiary
- Manufactured product sales 0.3%
Commercial supplies of ALT-B4 material
Revenue by region
- Overseas 88.64%
- South Korea 11.36%
Key metrics
| Revenue CAGR (5 years) | 38% |
|---|---|
| Operating income CAGR (5 years) | - |
| Net income CAGR (5 years) | - |
| Operating margin (5-year avg.) | -15% |
| ROE (5-year avg.) | 8% |
| ROA (5-year avg.) | 1% |
| Beta (5 years) | 1.04 |
| MDD (5 years) | - |
| Payout ratio (5-year avg.) | 3% |
| P/E | 74x |
| Forward P/E | 38x |
| PEG | - |